Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures

Gene Therapy

Volumn 21, Issue 1, 2014, Pages 106-114

  Kim, E K ^a   Seo, H S ^b   Chae, M J ^a   Jeon, I S ^b   Song, B Y ^b   Park, Y J ^a   Ahn, H M ^c   Yun, C O ^c   Kang, C Y ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

antitumor immunotherapy; B cell based vaccine; modified adenovirus (Ad k35)

Indexed keywords

ADENOVIRUS VECTOR; B LYMPHOCYTE VACCINE; B7 ANTIGEN; CANCER VACCINE; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 4; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; MURINAE; MUS;

ANIMALS; B-LYMPHOCYTES; CANCER VACCINES; CELLS, CULTURED; DEPENDOVIRUS; FEMALE; GENETIC VECTORS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NATURAL KILLER T-CELLS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891746605     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.65     Document Type: Article

References (45)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915. (Pubitemid 39273730)
2. Schreurs MW, Eggert AA, de Boer AJ, Figdor CG, Adema GJ. Generation and functional characterization of mouse monocyte-derived dendritic cells. Eur J Immunol 1999; 29: 2835-2841. (Pubitemid 30099008)
3. Elkord E, Williams PE, Kynaston H, Rowbottom AW. Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology 2005; 114: 204-212. (Pubitemid 40208937)
4. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117: 1195-1203. (Pubitemid 46718404)
5. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-277.
6. Chung Y, Kim BS, Kim YJ, Ko HJ, Ko SY, Kim DH et al. CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res 2006; 66: 6843-6850. (Pubitemid 44085645)
7. Kim YJ, Ko HJ, Kim YS, Kim DH, Kang S, Kim JM et al. Alpha- Galactosylceramideloaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity. Int J Cancer 2008; 122: 2774-2783. (Pubitemid 351631380)
8. Schultze JL, Grabbe S, von Bergwelt-Baildon MS. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol 2004; 25: 659-664. (Pubitemid 39457979)
9. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997; 100: 2757-2765. (Pubitemid 28007544)
10. Kim YJ, Han SH, Kang HW, Lee JM, Kim YS, Seo JH et al. NKT ligand-loaded, antigen-expressing B cells function as long-lasting antigen presenting cells in vivo. Cell Immunol 2011; 270: 135-144.
11. Appledorn DM, Patial S, McBride A, Godbehere S, Van Rooijen N, Parameswaran N et al. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 2008; 181: 2134-2144.
12. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996; 70: 6497-6501. (Pubitemid 26266881)
13. Xiang ZQ, Yang Y, Wilson JM, Ertl HC. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 1996; 219: 220-227. (Pubitemid 26180398)
14. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK et al. Replicationincompetent adenoviral vaccine vector elicits effective anti-immunodeficiencyvirus immunity. Nature 2002; 415: 331-335. (Pubitemid 34087555)
15. Tan Y, Hackett NR, Boyer JL, Crystal RG. Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirusbased vaccine encoding humanized protective antigen. Human Gene Ther 2003; 14: 1673-1682. (Pubitemid 37452877)
16. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55: 355-372. (Pubitemid 38316732)
17. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther 2009; 17: 1333-1339.
18. Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol 2009; 19: 165-178.
19. Kim YS, Kim YJ, Lee JM, Han SH, Ko HJ, Park HJ et al. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells. Human Gene Ther 2010; 21: 1697-1706.
20. Brouwer E, Havenga MJ, Ophorst O, de Leeuw B, Gijsbers L, Gillissen G et al. Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther 2007; 14: 211-219. (Pubitemid 46106964)
21. McVey D, Zuber M, Ettyreddy D, Reiter CD, Brough DE, Nabel GJ et al. Characterization of human adenovirus 35 and derivation of complex vectors. Virol J 2010; 7: 276.
22. Wu C, Lei X, Wang J, Hung T. Generation of a replication-deficient recombinant human adenovirus type 35 vector using bacteria-mediated homologous recombination. J Virological Methods 2011; 177: 55-63.
23. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81: 4654-4663. (Pubitemid 46668663)
24. Wang H, Liu Y, Li ZY, Fan X, Hemminki A, Lieber A. A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. Blood 2010; 115: 592-600.
25. Adams WC, Gujer C, McInerney G, Gall JG, Petrovas C, Karlsson Hedestam GB et al. Adenovirus type-35 vectors block human CD4\+ T-cell activation via CD46 ligation. Proc Natl Acad Sci USA 2011; 108: 7499-7504.
26. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408-1412. (Pubitemid 37466191)
27. Kanerva A, Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110: 475-480. (Pubitemid 38658011)
28. Kang E, Yun CO. Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity. BMB Rep 2010; 43: 781-788.
29. Choi JW, Lee JS, Kim SW, Yun CO. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Delivery Rev 2012; 64: 720-729.
30. Lee JS, Hur MW, Lee SK, Choi WI, Kwon YG, Yun CO. A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer. PloS One 2012; 7: e36520.
31. Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M et al. Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and-independent manners. Anticancer Res 2007; 27: 2311-2316. (Pubitemid 47228069)
32. Lee YS, Lee KA, Lee JY, Kang MH, Song YC, Baek DJ et al. An alpha-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine. Vaccine 2011; 29: 417-425.
33. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virusvaccinia infection. Proc Natl Acad Sci USA 2003; 100: 6753-6758. (Pubitemid 36666652)
34. Krishnan A, Wang Z, Srivastava T, Rawal R, Manchanda P, Diamond DJ et al. A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models. Immunol Lett 2008; 120: 108-116.
35. Shao HY, Lin YW, Yu SL, Lin HY, Chitra E, Chang YC et al. Immunoprotectivity of HLA-A2 CTL peptides derived from respiratory syncytial virus fusion protein in HLA-A2 transgenic mouse. PloS One 2011; 6: e25500.
36. Tan WG, Jin HT, West EE, Penaloza-MacMaster P, Wieland A, Zilliox MJ et al. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8\+ T cells induced by different adenovirus vectors. J Virol 2012; 87: 1359-1372.
37. Tsujimura A, Shida K, Kitamura M, Nomura M, Takeda J, Tanaka H et al. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem J 1998; 330: Pt 1 163-168. (Pubitemid 28075735)
38. Johnson MJ, Petrovas C, Yamamoto T, Lindsay RW, Lore K, Gall JG et al. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J Immunol 2012; 188: 6109-6118.
39. Deenick EK, Ma CS, Brink R, Tangye SG. Regulation of T follicular helper cell formation and function by antigen presenting cells. Curr Opin Immunol 2011; 23: 111-118.
40. King C, Sprent J. Emerging cellular networks for regulation of T follicular helper cells. Trends Immunol 2012; 33: 59-65.
41. Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Animal Sci 1999; 49: 179-188. (Pubitemid 29207285)
42. Peng S, Trimble C, He L, Tsai YC, Lin CT, Boyd DA et al. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(\+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Therapy 2006; 13: 67-77. (Pubitemid 41823853)
43. Kim J, Kim JH, Choi KJ, Kim PH, Yun CO. E1A-and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Human Gene Ther 2007; 18: 773-786. (Pubitemid 47502844)
44. Lee YS, Lee KA, Yoon HB, Yoo SA, Park YW, Chung Y et al. The Wnt inhibitor secreted frizzled-related protein 1 (sFRP1) promotes human Th17 differentiation. Eur J Immunol 2012; 42: 2564-2573.
45. Ko HJ, Kim YJ, Kim YS, Kim JM, Ho SH, Jeong JG et al. Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys. Gene Therapy 2008; 15: 1351-1360.